Cardiovascular Injury Due to SARS-CoV-2

Curr Clin Microbiol Rep. 2021;8(3):167-177. doi: 10.1007/s40588-021-00160-0. Epub 2021 Mar 5.

Abstract

Purpose of review: The world is currently facing the largest global health crisis since the early 1900s due to a novel coronavirus. While SARS-CoV-2 infection causes predictable symptoms in COVID-19 patients, including upper respiratory distress and fever, the heterogeneity of manifestations is surprising. This review focuses on direct and indirect causes of myocardial injury in COVID-19 patients and highlights current knowledge, treatment strategies, and outstanding questions in the field.

Recent findings: Data are emerging that highlight the extent of cardiovascular involvement in COVID-19 patients, including evidence that SARS-CoV-2 causes myocarditis and increases cardiac risk. The incidence of cardiac injury is much greater in patients with severe disease presentation and those in intensive care.

Summary: During the past year, COVID-19 patient mortality rates have improved due to tailored pharmacological treatments and patient management strategies that address the unique presentation of symptoms, which will hopefully also reduce the incidence of cardiac injury.

Keywords: Cardiac injury; Arrhythmia; COVID-19; Cardiomyopathy; Myocarditis.

Publication types

  • Review